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Background. High-risk sexual behaviors have been suggested as drivers of the recent dramatic increase of sex-
ually transmitted hepatitis C virus (HCV) among human immunodeﬁciency virus (HIV)–infected men who have sex
with men (MSM).
Methods. We assessed the association between the genetic bottleneck of HIV at transmission and the prevalence
and incidence of HCV coinfection in HIV-infected MSM from the Swiss HIV Cohort Study (SHCS). As a proxy for
the width of the transmission bottleneck, we used the fraction of ambiguous nucleotides detected by genotypic re-
sistance tests sampled during early HIV infection. We deﬁned a broad bottleneck as a fraction of ambiguous nucle-
otides exceeding a previously established threshold (0.5%).
Results. From the SHCS, we identiﬁed 671 MSM with available results of HCV serologic tests and with an HIV
genotypic resistance test performed during early HIV infection. Of those, 161 (24.0%) exhibited a broad HIV trans-
mission bottleneck, 38 (5.7%) had at least 1 positive HCV test result, and 26 (3.9%) had an incident HCV infection.
Individuals with broad HIV transmission bottlenecks exhibited a 2-fold higher odds of having ever experienced an
HCV coinfection (odds ratio, 2.2 [95% conﬁdence interval {CI}, 1.1–4.3]) and a 3-fold higher hazard of having an
incident HCV infection (hazard ratio, 3.0 [95% CI, 1.4–6.6]) than individuals with narrow HIV transmission
bottlenecks.
Conclusions. Our results indicate that the currently occurring sexual spread of HCV is focused on MSM who are
prone to exhibit broad HIV transmission bottlenecks. This is consistent with an important role of high-risk behavior
and mucosal barrier impairment in the transmission of HCV among MSM.
Keywords. HIV; hepatitis C virus; coinfection; transmission bottleneck; sexual transmission.
Hepatitis C virus (HCV) is a major cause of morbidity
and mortality, with 130–150 million infections
worldwide causing approximately 350 000 deaths/year
[1]. Until recently, sexual transmission of HCV was
considered an unlikely route of acquisition or was as-
sumed to play only a marginal role [2]. However, recent
outbreaks of HCV infection among human immunode-
ﬁciency virus (HIV)–infected men who have sex with
men (MSM) in several industrialized countries have
called these views into question [3–7]. The driving
mechanisms behind the recent change in the epidemi-
ology of HCV infection are unclear. The extent to which
sexual transmission occurs only or predominantly as a
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consequence of high-risk practices is especially unclear. Several
lines of evidence support this view, such as the absence of an
increased incidence of HCV infection in HIV-infected hetero-
sexuals [7] and the increased frequency of high-risk practices in
HCV/HIV-coinfected MSM [6].
The majority of sexually transmitted HIV infections are
founded by a single virus, such that the entire virus population
observed in an HIV-infected patient consists of the descendants
of a single transmitted virion [8]. This narrow genetic bottle-
neck at transmission (hereafter, the “transmission bottleneck”)
is reﬂected by the very low diversity observed in most recent
HIV infections. However, in a minority (10%–20%) of sexually
transmitted HIV infections, the transmission bottleneck is wide
[8–12]; that is, the infections are founded by ≥2 viruses and
accordingly exhibit a high genetic diversity even during the
early phase of infection. Intuitively, one would expect that the
chance of such a wide transmission bottleneck is larger for high-
risk sexual contacts, given that practices that increase the infec-
tion risk (ie, the transmission of at least 1 virion) should also
increase the chance that >1 virus is transmitted simultaneously
upon an infection event. To what extent this is the case is,
however, still an open question, as some studies conﬁrmed it
[10–12], while others failed to ﬁnd evidence for a wider trans-
mission bottleneck in HIV transmitted by high-risk sexual con-
tact [9].
Here, we used HIV/HCV-coinfection data from the Swiss
HIV Cohort Study (SHCS) and diversity measures derived
from the SHCS Drug Resistance Database (SHCS-DRDB) to as-
sess the association between the HIV bottleneck and the prev-
alence and incidence of HCV infections and (as an additional
indicator of high-risk behavior) of other sexually transmitted
infections. The SHCS is the ideal setting for this analysis be-
cause it is highly representative for the HIV-infected population
in Switzerland and because HCV-seronegative individuals en-
rolled in the SHCS have, since 1998, undergone testing at
least every 2 years for incident HCV infections.
METHODS
We considered the clinical and demographic data from the
SHCS and ambiguous-nucleotide scores derived from genotypic
resistance tests in the SHCS-DRDB. The SHCS is an open co-
hort with continuous enrollment of HIV-infected individuals
and semiannual follow-up visits [13]. In total, 18 200 individu-
als have been enrolled into the SHCS (as of December 2013). Of
those, 11 291 have at least 1 genotypic resistance test (GRT)
result in the SHCS-DRDB [13–15]. HCV status was ascertained
by enzyme-linked immunosorbent assays or by use of quantita-
tive polymerase chain reaction to detect HCV RNA (see the ar-
ticle by Wandeler et al [7] for more details). The SHCS was
approved by the individual local institutional review boards
of all participating centers (a list of the centers is available
at: http://www.shcs.ch/31-health-care-providers). Written in-
formed consent was obtained for each SHCS participant.
The size of the transmission bottleneck can be estimated
from the diversity observed in sequences sampled during
early infection [8]: if only 1 virus founds the new infection, di-
versity is low during early HIV infection; otherwise, diversity is
high. Elsewhere [16], we have shown that the fraction of ambig-
uous nucleotides ( fambiguous) is a good marker for viral diversity,
with an excellent correlation with clonal diversity in early infec-
tion. Therefore, we used this quantity with the threshold of
0.5% (established previously [16]) as a measure for the size of
the transmission bottleneck. Speciﬁcally, the transmission bot-
tleneck in a given patient was classiﬁed as wide if the earliest
GRT for that patient was performed on a sample obtained with-
in the ﬁrst year after HIV seroconversion and exhibited a high
diversity ( fambiguous≥ 0.5%). Conversely, the transmission bot-
tleneck was classiﬁed as narrow if the earliest GRT for that pa-
tient was performed on a sample obtained within the ﬁrst year
after HIV seroconversion and exhibited a low diversity
( fambiguous < 0.5%).
Since only diversity observed in early HIV-1 infection is in-
dicative of the width of the HIV transmission bottleneck, we
focus our analysis on individuals with an accurate estimate of
the infection date and a GRT performed on samples obtained
during early infection. The group of patients with an accurate
HIV infection/seroconversion date consisted of patients ful-
ﬁlling at least 1 of the following conditions: (1) negative and
positive HIV serologic test results <1 year apart, with the sero-
conversion date estimated as the midpoint between the last neg-
ative and the ﬁrst positive HIV test result; (2) presence of
symptoms indicating primary HIV infection (antiretroviral syn-
drome, as deﬁned by the SHCS [17]); and (3) participation in
the Zurich Primary HIV Infection Study [9].
Statistical analyses were performed in Stata, version 12.0. As-
sociations were assessed by univariable and multivariable logis-
tic regression and Cox proportional hazards model for HCV
infection incidence. In the logistic regression model, cases
were deﬁned as individuals who had at least 1 HCV-positive
test result recorded in the SHCS, and controls were deﬁned as
individuals who never had a positive result of a test for HCV. In
the Cox proportional hazards model for HCV infection inci-
dence, we focused on individuals whose ﬁrst HCV test result
was negative and for whom at least 1 subsequent test result
was available. Time at risk started at the time of this ﬁrst nega-
tive HCV test result and ended at the date of the last HCV test.
The multivariable models were adjusted for the potential con-
founders: laboratory that determined the sequences, year of
HIV seroconversion, and age at HIV seroconversion. The vari-
ables “laboratory” and “width of the transmission bottleneck”
were included as categorical variables, and the variables “year
of HIV seroconversion” and “age at HIV seroconversion”
were included as continuous variables. The validity of the
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proportional hazards assumptions were tested by Schoenfeld re-
siduals [18] and could not be rejected at a P value of .05.
RESULTS
Here, we assessed the relation between the size of the HIV trans-
mission bottleneck and the risk of acquiring an HCV coinfec-
tion. The size of the transmission bottleneck was derived from
the diversity detected by GRTs. A high HIV diversity indicates a
broad HIV transmission bottleneck only if the sample stems
from a recently infected patient. Therefore, we restricted our
analysis to patients for whom the SHCS and the SHCS-DRDB
contained both an accurate estimate of their date of HIV sero-
conversion and the result of a GRT that was performed within
the ﬁrst year after HIV seroconversion. A total of 1194 patients
fulﬁlled these 2 criteria. Because the HCV serostatus of individ-
uals enrolled in the SHCS has been systematically tested since
1998 (tests are performed on individuals at least every
2 years), we further restricted our analysis to patients with a
date of HIV seroconversion during 1998 or later (1104 pa-
tients). Accordingly, information on the HCV status was avail-
able for most of those individuals (1084 of 1104 patients). Since
sexually transmitted HCV has been observed almost exclusively
among MSM [3–7], the main analysis presented here focuses
on this transmission group. The MSM transmission group
was deﬁned as males in the SHCS who stated that their likely
route of acquiring HIV was homosexual sex and who did not
indicate any injection drug use at their follow-up visits. These
corresponded to 671 of 1084 patients with a GRT result from
early infection period and information on their HCV status
(Figure 1). Overall, we included all MSM in the SHCS with
an accurate estimation of their date of HIV seroconversion
after 1998 who had a GRT performed within 1 year of their es-
timated HIV seroconversion and for whom at least 1 HCV test
result was available (Figure 1). According to these criteria, 671
patients were included in the analysis (Table 1).
We found that HIV-infected MSM with a wide HIV trans-
mission bottleneck had a substantially higher risk of experienc-
ing an HCV coinfection: among HIV-infected MSM with a
narrow HIV transmission bottleneck, 4.5% (23 of 510) had
ever been coinfected with HCV, compared with 9.3% of HIV-
infected MSM (15 of 161) with a wide HIV bottleneck. This cor-
responds to an odds ratio (OR) of 2.2 (95% conﬁdence interval
[CI], 1.1–4.3). To assess the impact of the HIV bottleneck on
the HCV infection incidence, we focused on the 558 HIV-
infected MSM whose ﬁrst HCV test had a negative result and
for whom results of subsequent tests were available. If the
HIV transmission bottleneck was narrow, we found 14 HCV
infections in 2300 person-years, resulting in an HCV infection
incidence of 6 cases/1000 person-years. If the HIV transmission
bottleneck was broad, we found 12 infections in 656 person-
years, resulting in an HCV infection incidence of 18 cases/
1000 person-years. In a Cox proportional hazards model, we
found that the hazard ratio (HR) of HCV acquisition was
3.0 (95% CI, 1.4–6.6) if the HIV transmission bottleneck
was wide, compared with a narrow bottleneck (Figure 2).
Thus, both the prevalence and incidence of HCV coinfection
were >2-fold higher if the bottleneck at HIV transmission was
wide.
The associations between HCV infection incidence and prev-
alence on the one hand and the size of the HIV transmission
bottleneck on the other hand were not affected by age, year of
HIV seroconversion, or laboratory performing the GRT. The
analysis that controlled for these variables yielded an OR for ex-
periencing an HCV infection of 2.2 (95% CI, 1.1–4.4) and the
corresponding HR in the Cox proportional hazards model for
Figure 1. Flow diagram for the study population. The last selection (in
grey) corresponds to the subpopulation used for the analysis of incident
hepatitis C virus (HCV) infections. Abbreviations: GRT, genotypic resistance
test; HIV, human immunodeﬁciency virus; MSM, men who have sex with
men; SHCS, Swiss HIV Cohort Study.
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HCV infection incidence was 3.2 (95% CI, 1.5–6.9; Tables 2 and
3). Among the demographic confounders, 2 should be noted in
particular: the time of the GRT and the laboratory performing
the GRT. These variables are potential confounders because in
one of the laboratories the frequency of patients reporting a
GRT with an fambiguous value of ≥ 0.5% has increased over
time (because of a higher propensity of calling ambiguous
nucleotides in the laboratory; logistic regression OR, 1.1 per
year [95% CI, 1.0–1.2 per year]), while the incidence of HCV
infection has also increased over time in Switzerland [7]. How-
ever, because the incidence and HR remained almost un-
changed by controlling for laboratory and time of HIV
seroconversion in the multivariable models, this potential con-
founding has only a weak effect and cannot explain the observed
Table 1. Characteristics of the Study Population
Characteristic Without HCV With HCV Total P Valuea
HIV transmission bottleneck .03
Narrow 487 (95.5) 23 (4.5) 510 (100)
Broad 146 (90.7) 15 (9.3) 161 (100)
Age at HIV seroconversion, y 35 (28–41) 33 (27–41) 34 (28–41) .56
Year of HIV seroconversion 2007 (2004–2009) 2008 (2005–2009) 2007 (2004–2009) .39
Ethnicity .35
White 582 (94.0) 37 (6.0) 619 (100)
Not white 51 (98.1) 1 (1.9) 52 (100)
Laboratory .63
Zurich 294 (95.2) 15 (4.9) 309 (100)
Geneva 193 (93.2) 14 (6.8) 207 (100)
Lausanne 107 (93.0) 8 (7.0) 115 (100)
Basel 39 (97.5) 1 (2.5) 40 (100)
First available CD4+ T-cell count, cells/µL 470 (327–631) 464 (320–634) 470 (327–631) .8
First available HIV RNA value, log10 copies/mL 5.0 (4.4–5.9) 5.3 (4.5–6.7) 5.0 (4.4–5.9) .27
Data are no. (%) of study participants or median (interquartile range). The study population was defined as men who have sex with men, who had results of a
genotypic resistance test performed during early human immunodeficiency virus (HIV) infection, and who had results of at least 1 test for detection of hepatitis
C virus (HCV; Figure 1).
a By the Fisher exact test, for count data, and by the Wilcoxon rank sum test, for continuous variables.
Table 2. Results of Multivariable Logistic Regression Analysis
for Prevalent Cases of Hepatitis C Virus Infection
Factor
Univariable Analysis Multivariable Analysis
OR (95% CI)
P
Value OR (95% CI)
P
Value
HIV transmission
bottleneck
.02 .02
Narrow 1 (Reference) 1 (Reference)
Broad 2.17 (1.11–4.28) 2.21 (1.12–4.39)
Age at HIV
seroconversion
(per y)
0.99 (.96–1.03) .72 0.99 (.96–1.03) .66
Year of HIV
seroconversion
(per y)
1.04 (.94–1.14) .43 1.07 (.96–1.18) .23
Laboratory .55 .31
Zurich 1 (Reference) 1 (reference)
Geneva 1.42 (.67–3.01) 1.91 (.84–4.35)
Lausanne 1.42 (.67–3.01) 1.61 (.66–3.95)
Basel 0.50 (.06–3.91) 0.56 (.07–4.41)
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus;
OR, odds ratio.
Figure 2. Kaplan–Meyer estimates for hepatitis C virus (HCV) infection
incidence among patients with narrow (solid gray line) and broad (dashed
black line) transmission bottlenecks. The graph has been truncated when
the number of patients at risk in the smaller stratum was <10 (see Supple-
mentary Figure 1 for a version of the graph without truncation). The log-
rank test was performed on the nontruncated data.
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association between diversity and HCV coinfection risk. Be-
cause of the small numbers of HCV infections in our study pop-
ulation (38 patients who ever had an HCV infection, and 26
with incident HCV infection), we did not include additional
covariables in the multivariable models shown in Tables 2
and 3. However, we found similarly strong effects of the trans-
mission bottleneck (OR > 2 and HR > 3) when additionally ad-
justing for the other variables listed in Table 1.
DISCUSSION
Here, we have shown that HIV-infected MSM from the SHCS
who experienced a broad HIV transmission bottleneck had a
>3-fold higher risk of acquiring HCV. This result is robust
against correction for potential demographic confounders
such as age, calendar year, or the laboratory performing the
GRT. Our ﬁnding suggests that the HCV epidemic among
MSM is currently focused on individuals who were also prone
to experience a broad transmission bottleneck.
In this study, we focused on MSM because the recent increase
in HCV infection incidence has so far been found only in this
transmission group [3–7]. We extended our analysis to other
transmission groups but did not ﬁnd signiﬁcant associations be-
tween the size of the transmission bottleneck and the risk of an
HCV infection for individual transmission groups other than
MSM (data not shown). It should be noted that the number
of individuals with GRTs available for early infection was
much smaller for these transmission groups (Figure 1). More-
over, a test for homogeneity could not reject the null-hypothesis
that the ORs are the same across groups (P = .33). Thus, because
of the limited data available, it is currently unclear whether this
association between the transmission bottleneck and the risk of
an HCV infection also extends to other transmission groups.
Previous work has shown an association between high-risk
sexual practices and both the risk of HCV infection [3–7] and
a broader HIV transmission bottleneck, although the latter as-
sociation has not been found in all studies [8–12]. Similarly, in-
jection drug use has also been associated with a broad HIV
transmission bottleneck [19]. In the light of these previous stud-
ies on both high-risk sex and injection drug use, our results can
be explained as follows: MSM engaging in high-risk behavioral
practices have a larger chance of experiencing both a wide HIV
transmission bottleneck and infection with HCV. Hence, a wide
transmission bottleneck is an indicator for high-risk behavior
and therefore for an increased risk of an HCV transmission.
Even though the association between broad HIV transmis-
sion bottlenecks and HCV infection might have been caused
by undisclosed injection drug use among the MSM population,
we believe that high-risk sexual behavior is a more likely cause
for the association. It should be noted that the SHCS collects
very detailed information on injection drug use at the semian-
nual follow-up visits and that even a single report of injection
drug use in a follow-up visit led to exclusion from our study
population, thereby minimizing the potential problem of undis-
closed injection drug use. Moreover, similar to Wandeler et al
[7],we found that the incidence of HCV infection was positively
associated with reporting unprotected sex and with a history of
concomitant syphilis, highlighting the role of sexual transmis-
sion (data not shown). Including those factors into the multivar-
iate model for HCV infection incidence (summarized in Table 3)
caused only minor changes in the effect of a broad bottleneck (ad-
justed HR, 2.8). In addition, in a large molecular epidemiology
study, we have clearly shown that HIV sequences fromMSMhard-
ly ever cluster together with those of injection drug users (≤2%),
thus rendering injection drug use highly unlikely as a confounder
[20]. Finally, in recent work [21] we found that the prevalence
and incidence of HCV coinfection in HIV-infected MSM is
clearly associated with the HIV phylogeny, which again provides
evidence that at least some cases of transmission occur via sex.
One may speculate that a wide HIV transmission bottleneck
and an increased risk for HCV coinfection are linked because
both are facilitated by high-risk, traumatic sex causing breach-
es/impairment of the mucosal barrier during sexual transmis-
sion. This interpretation of the results (but not the results as
such) assumes that the risk behavior at the time point of HIV
acquisition is indicative of the behavior during later time points.
This assumption still allows for changes of risk behavior over
time because it only involves the much weaker requirement
that some residual correlation persists over time. An alternative
mechanism that may cause the observed association is that
syphilitic ulcers increase the probability both for broad HIV
transmission bottlenecks and for HCV coinfection. Individuals
Table 3. Results of Multivariable Cox Proportional Hazards
Modeling for Incident Hepatitis C Virus Infection
Factor
Univariable Analysis Multivariable Analysis
HR (95% CI)
P
Value HR (95% CI)
P
Value
HIV transmission
bottleneck
.005 .004
Narrow 1 (Reference) 1 (Reference)
Broad 3.02 (1.40–6.55) 3.17 (1.45–6.91)
Age at HIV
seroconversion
(per y)
0.96 (.91–1.01) .12 0.96 (.91–1.01) .11
Year of HIV
seroconversion
(per y)
1.60 (1.28–2.00) <.001 1.62 (1.29–2.02) <.001
Laboratory .2 .08
Zurich 1 (Reference) 1 (Reference)
Geneva 0.85 (.33–2.19) 1.61 (.62–4.13)
Lausanne 1.76 (.66–4.74) 1.87 (.69–5.11)
Basel 0 0
Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus;
HR, hazard ratio.
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with a broad HIV transmission bottleneck exhibited a slight but
nonsigniﬁcant increase in the risk of a syphilis coinfection (OR,
1.23 [95% CI, .86–1.8]), lending partial support for this alter-
nate mechanism. Finally, we found that 24 of 26 incident
HCV infections occurred after antiretroviral therapy initiation
and that the 2 individuals who acquired HCV while therapy
naive exhibited both a narrow HIV transmission bottleneck.
However, this association is not signiﬁcant (P = .48, by the Fish-
er exact test), and it is not clear which mechanism could have
generated the association. Independently of these possible inter-
pretations, our results indicate that HCV coinfections are cur-
rently focused on a subgroup of MSM: namely those who—for
behavioral or biological reasons—are more prone to experience
a broad bottleneck at HIV transmission.
This study has several limitations. First, the propensity of
calling ambiguous nucleotides might vary between laboratories
and over time. In fact, we found such an effect of time for one
laboratory. However, our results remained robust after control-
ling for laboratory and year of HIV seroconversion in multi-
variable models, indicating that this effect did not have a
major impact on our results. Second, our interpretation that
high-risk sex is causing the association between HCV infections
and a broad HIV transmission bottleneck hinges on the
assumption that undisclosed injection drug use is negligible.
Finally, our study has been conducted in the particular epidemi-
ological setting of the SHCS, and it remains to be shown wheth-
er similar effects occur also in other settings. This problem is
mitigated by the fact that the rise of sexually transmitted
HCV has occurred in a similar way (eg, with similar time scales
and populations at risk) in many different industrialized coun-
tries [3–7]. This suggests that high-risk sexual behavior might
also play a similar role across epidemiological settings.
Overall, our results show that HCV transmission among MSM
occurs preferentially among individuals who also exhibit a broad
HIV transmission bottleneck. From a general perspective, this
provides a proof of principle of how molecular tools can be
used to identify core groups for disease transmission. For
HCV, it indicates that high-risk behavioral transmission and pos-
sibly high-risk sexual behavior leading to mucosal breaches may
have played an important role in the recent transition of HCV
from an almost uniquely parenterally transmitted pathogen to
one that is transmitted, in at least some cases, via sex.
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